Prelude Therapeutics (PRLD) Gains from Investment Securities (2019 - 2026)
Prelude Therapeutics' (PRLD) quarterly Gains from Investment Securities came in at $583766.0 in Q1 2026, up 15027.39% year-on-year from N/an in Q1 2025, and up 1596.84% quarter-over-quarter from -$39000.0 in Q4 2025.
Prelude Therapeutics (PRLD) Gains from Investment Securities (2019 - 2026) Analysis & Trends
Prelude Therapeutics has disclosed Gains from Investment Securities across 8 years of filings, most recently posting $583766.0 for Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $583766.0, up 15027.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $583766.0 (up 15027.39% YoY), and the FY2025 annual result was $14.7 million, up 275.44% from the prior year.
- Gains from Investment Securities came in at $583766.0 for Q1 2026 at Prelude Therapeutics, up from -$39000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $15.5 million in Q3 2025 to a low of -$39000.0 in Q4 2025.
- The 5-year median for Gains from Investment Securities is $267355.0 (2023), against an average of $1.8 million.
- Peak annual rise in Gains from Investment Securities reached 416415.64% in 2025, while the deepest fall reached 657.14% in 2025.
- Prelude Therapeutics' Gains from Investment Securities stood at $875000.0 in 2022, then decreased by 5.37% to $828000.0 in 2023, then plunged by 99.15% to $7000.0 in 2024, then sank by 657.14% to -$39000.0 in 2025, then soared by 1596.84% to $583766.0 in 2026.
- The last three Gains from Investment Securities figures came in at $583766.0 (Q1 2026), -$39000.0 (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Prelude Therapeutics | 314.40 Mn | 169.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 583,766.00 |
| Mar 31, 2026 | 583,766.00 |
| Dec 31, 2025 | -39,000.00 |
| Dec 31, 2025 | -39,000.00 |
| Sep 30, 2025 | 15.50 Mn |
| Sep 30, 2025 | 15.50 Mn |
| Jun 30, 2025 | 3,355.00 |
| Jun 30, 2025 | 3,355.00 |
| Mar 31, 2025 | 3,859.00 |
| Mar 31, 2025 | 3,859.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | 3,722.00 |
| Sep 30, 2024 | 3,722.00 |
| Jun 30, 2024 | 3,722.00 |
| Jun 30, 2024 | 3,722.00 |
| Mar 31, 2024 | 4,285.00 |
| Mar 31, 2024 | 4,285.00 |
| Dec 31, 2023 | 828,000.00 |
| Dec 31, 2023 | 828,000.00 |